In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

Pfaller, M. A.; Boyken, L.; Hollis, R. J.; Messer, S. A.; Tendolkar, S.; Diekema, D. J.

doi:10.1128/jcm.43.11.5425-5427.2005

Cited by 161Antifungal resistance and susceptibilityFungal Plant Pathogen ControlYeasts and Rust Fungi Studies

In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

Open access

Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J.·2005·Journal of Clinical Microbiology

DOI 10.1128/jcm.43.11.5425-5427.2005PMC PMC1287823

Open this paper in CoChat — free account

Abstract

Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp. We assessed the in vitro activity of anidulafungin against 2,235 clinical isolates of Candida spp. using the CLSI broth microdilution method. Anidulafungin was very active against Candida spp. (the MIC at which 90% of strains are inhibited [MIC(90)] was 2 microg/ml when MIC endpoint criteria of partial inhibition [MIC-2] were used). Candida albicans, C. glabrata, C. tropicalis, C. krusei, and C. kefyr were the most susceptible species of Candida (MIC(90), 0.06 to 0.12 microg/ml), and C. parapsilosis, C. lusitaniae, and C. guilliermondii were the least susceptible (MIC(90), 0.5 to 2 microg/ml). In addition, 315 fluconazole-resistant isolates were tested, and 99% were inhibited by < or =1 microg/ml of anidulafungin. These results provide further evidence for the spectrum and potency of anidulafungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.

Integrity signals

Registry

Crossref · 10.1128/jcm.43.11.5425-5427.2005

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Triazole-resistant clinical isolates and laboratory strains that demonstrate increased drug efflux pump expression remain susceptible to the echinocandins in laboratory liquid assays.
“Triazole-resistant clinical isolates (Pfaller et al., 2005; Messer et al., 2006) and laboratory strains (Niimi et al., 2006) that demonstrate increased drug efflux pump expression remain susceptible to the echinocandins in laboratory liquid assays.”
From Genetic Drivers of Multidrug Resistance in Candida glabrata (2016) · cites this paper as Pfaller et al., 2005
Interpretive breakpoints for fluconazole, itraconazole, voriconazole, and flucytosine have been developed by considering data relating MICs to known resistance mechanisms, MIC distribution profiles, pharmacokinetic and pharmacodynamic parameters, and the relationship between in vitro activity and clinical outcomes.
“Interpretive breakpoints for four systemically active antifungal agents (fluconazole, itraconazole, voriconazole, and flucytosine [5FC]) have been developed”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [225]
These CLSI methods are reproducible and accurate and provide clinically useful information comparable to that of antibacterial testing.
“These methods are reproducible and accurate and provide clinically useful information that is comparable to that of antibacterial testing (223, 225, 226, 253).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [225]
In vitro cross-resistance to voriconazole is distinctly uncommon with C. krusei, in contrast to C. glabrata.
“In contrast to C. glabrata , however, in vitro cross-resistance to voriconazole is distinctly uncommon with C. krusei (225)”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [225]
The in vitro activity of voriconazole translates into clinical success in patients infected with C. krusei.
“It also appears that the in vitro activity of voriconazole translates into clinical success in patients infected with C. krusei (123, 182, 225).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [225]

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736 · see citing works
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,435 · see citing works
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494 · see citing works
Candida, Cryptococcus, and Other Yeasts of Medical Importance
Howell, S. A., & Hazen, K. C. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch115 · Cited by 249 · see citing works
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
Barry, A. L., Pfaller, M. A., Brown, S. D., Espinel-Ingroff, A., Ghannoum, M. A., Knapp, C., Rennie, R. P., Rex, J. H., & Rinaldi, M. G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3457-3459.2000 · Cited by 211 · see citing works
Self-citation
Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformans
Ernst, E. J., Klepser, M. E., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1108-1111.2000 · Cited by 181 · see citing works
Self-citation
Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia
Krause, D. S., Reinhardt, J. F., Vázquez, J. A., Reboli, A. C., Goldstein, B. P., Wible, M., & Henkel, T. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2021-2024.2004 · Cited by 177 · see citing works
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species
Odds, F. C., Motyl, M. R., Andrade, R. A., Billé, J., Cantón, E., Cuenca‐Estrella, M., Davidson, A. D., Durussel, C., Ellis, D., Foraker, E., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3475-3482.2004 · Cited by 173 · see citing works
Self-citation
Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling
Groll, A. H., Mickiene, D., Petraitienė, R., Petraitis, V., Lyman, C. A., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2845-2855.2001 · Cited by 137 · see citing works
Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida
Pfaller, M. A., Messer, S. A., Boyken, L. B., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5729-5731.2003 · Cited by 107 · see citing works
Self-citation
Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits
Petraitienė, R., Petraitis, V., Groll, A. H., Candelario, M., Sein, T., Bell, A., Lyman, C. A., McMillian, C. L., Bacher, J., & Walsh, T. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2148 · Cited by 103 · see citing works
Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates
Pfaller, M. A., Messer, S. A., Boyken, L. B., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3117-3119.2004 · Cited by 90 · see citing works
Self-citation
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents
Pfaller, M. A., Messer, S. A., & Coffman, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.763 · Cited by 85 · see citing works
Self-citation
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
Uzun, Ö., Kocagöz, S., Cetinkaya, Y. S., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1156 · Cited by 72 · see citing works
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method
Arévalo, M. P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg018 · Cited by 68 · see citing works
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
Cuenca‐Estrella, M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.475 · Cited by 63 · see citing works
Influences of Methodological Variables on Susceptibility Testing of Caspofungin against Candida Species and Aspergillus fumigatus
Bartizal, C., & Odds, F. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2100-2107.2003 · Cited by 60 · see citing works
Anidulafungin: an echinocandin antifungal
Pfaller, M. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1183 · Cited by 37 · see citing works
Self-citation
Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents
Zhanel, G. G., Karlowsky, J. A., Zelenitsky, S. A., Turik, M. A., & Hoban, D. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2446 · Cited by 18 · see citing works

Flagged first, then by citations

Sorted by citations

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · see citing works
Self-citation
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · see citing works
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · see citing works
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376 · see citing works
Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377 · see citing works
Self-citation
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327 · see citing works
A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis , Candida orthopsilosis , and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323 · see citing works
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285 · see citing works
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250 · see citing works
Self-citation
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226 · see citing works
Self-citation
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213 · see citing works
Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Lee, K. K., MacCallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. R., & Munro, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-11 · Cited by 209 · see citing works
The Echinocandins
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205 · see citing works
Contemporary tools for the diagnosis and management of invasive mycoses
Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147 · see citing works
Self-citation
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145 · see citing works
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140 · see citing works
Self-citation
Molecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128 · see citing works
Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains
Castanheira, M., Woosley, L. N., Diekema, D. J., Messer, S. A., Jones, R. N., & Pfaller, M. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01711-09 · Cited by 125 · see citing works
Self-citation
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118 · see citing works
Echinocandins: the expanding antifungal armamentarium
Aguilar-Zapata, D., Petraitiene, R., & Petraitis, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ814 · Cited by 112 · see citing works
Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-06 · Cited by 98 · see citing works
Genetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93 · see citing works
Echinocandins: A ray of hope in antifungal drug therapy
Grover, N. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.62396 · Cited by 75 · see citing works
Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species.
Jensen, R. H., & Arendrup, M. C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02071-10 · Cited by 68 · see citing works
Sphingolipids Mediate Differential Echinocandin Susceptibility in Candida albicans and Aspergillus nidulans
Healey, K. R., Challa, K. K., Edlind, T. D., & Katiyar, S. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04667-14 · Cited by 23 · see citing works

Medical Claims and Current Applications of the Potent Echinocandin Antifungals
Smith, L., & Lu, S. (2009) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489110790112563 · Cited by 2 · see citing works
Anidulafungin;a new echinocandin antifungal agent
De-xing, F. (2005) · Chinese New Drugs Journal
Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
Tóth, Z., Forgács, L., Kardos, T., Kovács, R., Locke, J. B., Kardos, G., Nagy, F., Borman, A. M., Adnan, A., & Majoros, L. (2020) · Journal of Fungi · doi:10.3390/jof6030136 · Cited by 20 · see citing works
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213 · see citing works
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26 · see citing works

Authors: Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J.
Affiliations: Departments of Pathology
University of Iowa (US)
Corresponding author: Pfaller, M. A.
ORCID: Pfaller, M. A.
Hollis, R. J.
Messer, S. A.
Diekema, D. J.
Venue: Journal of Clinical Microbiology
Publisher: American Society for Microbiology
Published: 2005-11
Volume: 43
Issue: 11
Pages: 5425-5427
ISSN: 0095-1137 (ISSN-L)
1098-660X
DOI: 10.1128/jcm.43.11.5425-5427.2005
PMC: PMC1287823
OpenAlex: W2098505026
Cited by: 161
References: 19
Citations by year: 2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 6 · 2015: 7 · 2014: 4 · 2013: 5 · 2012: 5
FWCI: 13.22
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Clinical Microbiology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
Keywords: anidulafungin, echinocandins, Candida, antifungal susceptibility, fluconazole resistance, Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei, Candida kefyr, Candida parapsilosis, Candida lusitaniae, Candida guilliermondii, minimum inhibitory concentration, clinical isolates
MeSH terms: Anidulafungin, Antifungal Agents, Candida, Candidiasis, Humans, Microbial Sensitivity Tests, Peptides, Cyclic, Fluconazole, Drug Resistance, Fungal, Echinocandins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks